Drug Trial Radar · NCT03778996
SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Actual
Start
Jan 3, 2020
Primary completion
Dec 19, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Sarcoma Oncology Research Center, LLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tyme, Inc
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: * Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion of systemic treatment * Clinically advanced sarcoma patients in the salvage treatment setting Up to 24 efficacy evaluable patients (up to 12 per cohort) will be enrolled. Study patients will receive oral SM-88, with scheduled safety and efficacy evaluations.
Conditions
- Sarcoma, Ewing
- Sarcoma
Interventions
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)Drug
Daily oral combination therapy for cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: Every 3 months for up to 2 years
- Stable Disease for at Least 3 MonthsTime frame: Every 3 months for up to 2 years
- Progression Free Survival on Study of at Least 1.5 Times the Duration of PFS for the Last Prior TreatmentTime frame: Every 3 months for up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sarcoma Oncology Research Center
Santa Monica, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.